Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK p.Ile1171Thr (p.I1171T) ALK p.Ile1171Thr (p.I1171T)
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily). The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance). MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib). About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild-type.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1287
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/527
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 25228534
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Resitance or Non-Reponse | true |